Alterations of the p53, p21, p16, p15 and RAS genes in childhood T-cell acute lymphoblastic leukemia

Leukemia Research

Volumn 23, Issue 2, 1999, Pages 115-126

  Kawamura, Machiko ^a   Ohnishi, Hiroaki ^a   Guo, Shu Xia ^a   Sheng, Xiao Ming ^a   Minegishi, Masayoshi ^b   Hanada, Ryoji ^c   Horibe, Keizo ^d   Hongo, Teruaki ^e   Kaneko, Yasuhiko ^f   Bessho, Fumio ^a   Yanagisawa, Masayoshi ^a   Sekiya, Takao ^g   Hayashi, Yasuhide ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b Inst Devmt Aging Cancer T   (Japan)

^c SAITAMA CHILDREN'S MEDICAL CENTER   (Japan)

^d NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f SAITAMA CANCER CENTER   (Japan)

^g NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Childhood; p15 and RAS genes; p16; p21; p53; T cell acute lymphoblastic leukemia

Indexed keywords

PROTEIN P15; PROTEIN P16; PROTEIN P21; PROTEIN P53; RAS PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLELE; ARTICLE; CANCER CELL CULTURE; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; ONCOGENE RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; T CELL LEUKEMIA; TUMOR SUPPRESSOR GENE;

ADOLESCENT; BASE SEQUENCE; CELL CYCLE PROTEINS; CHILD; CHILD, PRESCHOOL; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FEMALE; GENES, P16; GENES, P53; GENES, RAS; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LEUKEMIA, T-CELL, ACUTE; MALE; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0032932735     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(98)00146-5     Document Type: Article

References (72)

1. Pullen D., Falletta J., Crist W., Vogler L., Dowell B., Humphrey G., Blackstock R., van Eys J., Cooper M., Metzgar R., Meydrech E. Southwest Oncology Group experience with immunological phenotyping in acute lymphocytic leukemia of childhood. Cancer Res. 41:1981;4802.
2. Pui C.-H., Behm F., Crist W. Clinical and biological relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood, 82:1993;343.
3. Sallan S., Ritz J., Pesado J., Gelber R., O'Brien C., Hitchcock S., Coral F., Schlossman S. Cell surface antigens: prognostic implications in childhood acute lymphoblastic leukemia. Blood, 55:1980;395.
4. Greaves M., Janossy G., Peto J., Kay H. Immunologically defined subclasses of acute lymphoblastic leukemia in children: their relationship to presentation features and prognosis. Br J Haematol. 48:1981;179.
5. Pui C.-H., Behm F., Singh B., Schell M., Williams D., Rivera G., Kalwinsky D., Mirror J., Dodge R., Sandlund J., Crist W., Raimondi S. Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia. Blood. 75:1990;174.
6. Shuster J., Falletta J., Pullen D., Crist W., Humphrey G., Dowell B., Wharam M., Borowitz M. Prognostic factors in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood. 75:1990;166.
7. Rivera G., Raimondi S., Hancock M., Behm F., Pui C.-H., Abromowitch M., Mirro J., Ochs J., Look A., Williams D., Murphy S., Dahl G., Kalwinsky D., Evans W., Kun L., Simone J., Crist W. Improved outcome in childhood acute lymphoblastic leukemia with reinforced early treatment and rotational combination chemotherapy. Lancet. 337:1991;61.
8. Raimondi S., Behm F., Roberson P., Pui C., Rivera G., Murphy S., William D. Cytogenetics of childhood T-cell leukemia. Blood. 72:1988;1560.
9. Kaneko Y., Frizzera G., Shikano T., Kobayashi H., Maseki N., Sakurai M. Chromosomal and immunophenotypic patterns in T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma(LBL). Leukemia. 3:1989;1989.
10. Chen Q., Cheng J.T., Tsai L.H., Schneider N., Buchanan G., Carroll A., Cris W., Ozanne B., Siciliano M.J., Baer R. The tal gene undergoes chromosome translocation in T cell leukemia and potentially encodes a helix-loop-helix protein. EMBO J. 9:1990;415.
11. Hayashi Y., Raimondi S., Look A.T., Behm F., Kitchingham G., Pui C., Rivera G., Williams D. Abnormalities of the long arm of chromosome 6 in childhood acute lymphoblastic leukemia. Blood. 76:1990;1926.
12. Serrano M., Hannon G.J., Beach D. A new reguratoly motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature. 366:1993;704.
13. Kamb A., Gruis N.A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtian S.V., Stockert E., Day III R.S., Johnson B.E., Skolnick M.H. A cell cycle regulator potentially involved in genesis of many tumor type. Science. 264:1994;436.
14. Nobori T., Miura K., Wu D., Lois A., Takabayashi K., Carson D. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 368:1994;753.
15. Hirama T., Koeffler H. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood. 86:1995;841.
16. Ohnishi H., Kawamura M., Ida K., Sheng X.M., Hanada R., Nobori T., Yamamori S., Hayashi Y. Homozygous deletions of p16/MTS1 gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia. Blood. 86:1995;1269.
17. Hebert J., Cayuela J., Berkeley J., Sigaux F. Candidate tumor-suppressor genes MTS1 (p161N4A) and MTS2 (p151NK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemia. Blood. 84:1994;4038.
18. Merlo A., Herman J.G., Mao L., Lee D.J., Gabrielson P., Burger P.C., Baylin S.B., Sidransky D. 5′CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat Med. 7:1995;686.
19. Nigro J., Baker S., Preisinger A., Jessup J., Hostetter R., Cleary K., Binger S., Davidson N., Baylin S., Devilee P., Glover T., Collins F., Weston A., Modali R., Harris C., Vogelstein B. Mutations in p53 gene occur in diverse human types. Nature. 342:1989;705.
20. Jonveaux P., Fenaux P., Quiandon I., Pignon J., Lai J., Loucheux-Lefebre M., Goosens M., Bauters F., Berger R. Mutations in the p53 gene in myelodysplastic syndromes. Oncogene. 6:1991;2243.
21. Feinstein E., Cimino G., Gale R., Alimene G., Berthier R., Kishi K., Goldman J., Zaccaria A., Berrebi A., Canaani E. p53 in chronic myelogenous leukemia in acute phase. Proc Natl Acad Sci USA. 88:1991;6293.
22. Slingerland J., Minden M., Benchimol S. Mutations of the p53 gene in human acute myelogenous leukemia. Blood. 77:1991;1500.
23. Sugimoto K., Toyoshima H., Sasaki R., Miyagawa K., Hagiwara K., Ishikawa F., Yazaki Y., Hirai H. Frequent mutations in the p53 gene in human myeloid leukemia cell lines. Blood. 79:1992;2378.
24. Gaidano G., Ballerin P., Gong J., Inghirami G., Neri A., Newcomb E., Magrath I., Knowles D., Dalla-Favera R. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 88:1991;5413.
25. Ichikawa A., Hotta T., Takagi N., Tsushita K., Kinoshita T., Nagai H., Murakami Y., Hayashi K., Saitoh H. The pattern of p53 mutations in B-cell lymphoma. Blood. 79:1992;2701.
26. Fenaux P., Jonveaux P., Quiquandon I., Preudhomme C., Luc L.J., Vaurumbeke M., Loucheux-Lefebvre M., Bauters F., Berger R., Kerckaert J. Mutations of the p53 gene in B-cell lymphoblastic acute leukemia: a report on 60 cases. Leukemia. 6:1992;246.
27. Neri A., Baldini L., Trecca D., Cro L., Polli E., Maiolo A. p53 mutations in multiple myeloma are associated with advanced forms of malignancy. Blood. 81:1993;128.
28. Imamura J., Miyoshi I., Koeffler H.P. p53 in hematologic malignancies. Blood. 84:1994;2412.
29. Cheng J., Haes M. Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell line. Mol Cell Biol. 10:1990;5502.
30. Kastan M., Onyekwere O., Sidransky D., Vogelstein B., Craig R. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:1991;6304.
31. Shaw P., Bovey R., Tudy S., Sahli R., Sordat B., Costa J. Induction of apoptosis by wild-type p53 in a human colon tumor derived cell line. Proc Natl Acad Sci USA, 89:1992;4495.
32. El-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Merce W.E., Kinzler K.W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817.
33. Harper J., Adam G., Wei N., Keyomarsi K., Elledge S. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 75:1993;805.
34. Xiong Y., Hannon G., Zhang H., Casso D., Kobayashi R., Beach D. p21 is a universal inhibitor of cyclin kinases. Nature. 366:1993;701.
35. El-Deiry W.S., Harper J.W., O'Connor P.M., Velculescu V.E., Canman C.E., Jackman J., Pietenpol J.A., Burrell M., Hill D.E., Wang Y., Wiman K.G., Mercer W.E., Kastan M.B., Kohn K.W., Elledge S.J., Kinzler K.W., Vogelstein B. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54:1994;1169.
36. Bos J. Ras oncogene in human cancer. A review. Cancer Res. 49:1989;4682.
37. Lubbert M., Mirro J., Miller C., Kahan J., Isaac G., Kitchingman G., Merteilsmann R., Herrmann F., McCormic F., Koeffler H.P. N-ras gene point mutations in childhood acute lymphoblastic leukemia correlate with a poor prognosis. Blood. 75:1990;1163.
38. Hayashi Y., Eguchi M., Sugita K., Nakazawa S., Sato T., Kojima S., Bessho F., Konishi S., Inaba T., Hanada R., Yamamoto K. Cytogenetic findings and clinical features in acute leukemia and transient myeloproliferative disorder in Down's syndrome. Blood. 72:1988;15.
39. Kikuchi A., Hayashi Y., Kobayashi S., Hanada R., Moriwaki K., Yamamoto K., Fujimoto J., Kaneko Y., Yamamori S. Clinacal significance of TAL1 gene alteration in childhood T-cell acute lymphoblastic leukemia and lymphoma. Leukemia. 7:1993;933.
40. Tsuchida M, Akatsuka J, Bessho F, Chihara H, Hayashi Y, Hoshi Y, Hosoya R, Furukawa T, Ikuta K, Inana I, Ishikawa A, Ishimoto K, Ito K, Kaneko M, Kaneko T, Kato S, Komiyama J, Matsuyama S, Nagao T, Nakazawa S, Nishihara K, Ohira M, Okimoto Y, Ohkawa Y, Ohtsuki H, Sato T, Shibuya A, Shitara T, Sugita T, Taguchi N, Torigoe K, Tsukada M, Tsukimoto I, Tsunematsu Y, Wada E, Yamada K, Yamamoto K, Yamamoto M, Yata J, Nishimura K, Saito T. Treatment of acute lymphoblastic leukemia in the Tokyo children's Cancer Study group: preliminary result of L84-11 protocol. Acta Pediatr Jpn 1991;33:522.
41. Horibe K., Katayama I., Miyajima Y., Matsumoto K., Fukuda M., Yoshida J., Kudo K., Kato K., Kojima S., Matsuyama T. Outcome of treatment protocol 8704T for childhood T cell leukemia and lymphoma. Jpn J Clin Hematol (Rinketsu). 35:1994;657.
42. Minegishi M., Tuchlya S., Minegishi N., Yoshie O., Nakamura M., Konno T. Characterization of a precursor T-cell line (THP-6) with rearranged T-cell receptor β chain gene. Leuk Res. 12:1988;227.
43. Minegishi M., Minegishi N., Yanagisawa T., Tsuchiya S., Tezuka H., Kaji M., Nakamura M., Hayashi Y., Konno T. A human CD4- CD8- T cell receptorαβ+ T leukemic cell line undergoing phytohemagglutin-induced apoptosis. Leuk Res. 19:1995;433.
44. Hayashi Y., Kawamura M., Kobayashi S., Moriwaki K., Kobayashi M., Bessho F., Hanada R., Yamamoto K., Mori T., Nakazawa S., Yaginuma Y., Honma Y., Hozumi M. Establishment and characterization of cell lines derived from childhood leukemias. Int J Hematol. 57:1993;124.
45. Komuro H., Hayashi Y., Kawamura M., Hayashi K., Kaneko Y., Kamoshita S., Hanada R., Yamamoto K., Hongo T., Yamada M., Tsuchida Y. Mutations of the p53 gene are involved in Ewing's sarcoma but not in neuroblastomas. Cancer Res. 53:1993;5284.
46. Kawamura M., Kikuchi A., Kobayashi S., Hanada R., Yamamoto K., Horibe K., Shikano T., Ueda K., Hayashi K., Seklya T., Hayashi Y. Mutations of the p53 and ras gene in childhood t(1;19)-acute lymphoblastic leukemia. Blood. 85:1995;2546.
47. Shimizu T., Miwa W., Nakamori S., Ishikawa O., Konishi Y., Seklya T. Absence of mutation of the p21/WAF1 gene in human lung and pancreatic cancers. Jpn J Cancer Res. 87:1996;275.
48. Sheng X.M., Kawamura M., Ohnishi H., Ida K., Hanada R., Kojima S., Kobayashi M., Bessho F., Yanagisawa M., Hayashi Y. Mutations of the ras genes in childhood acute myeloid leukemia, myelodysplastic syndrome and juvenile chronic myelocytic leukemia. Leuk Res. 21:1997;697.
49. Ohnishi H., Hanada R., Horibe K., Hongo T., Kawamura M., Naritaka S., Bessho F., Yanagisawa M., Nobori T., Yamamori S., Hayashi Y. Homozygous deletions of p16/MTS1 and p15/MTS2 genes are frequent in t(1;19)negative, but not in t(1;19)-positive B precursor acute lymphoblastic leukemia in childhood. Leukemia. 10:1996;1104.
50. Lo K.W., Cheung S.T., Leung S.F., Hasselt A.V., Tsang Y.S., Mak K.F., Chung Y.F., Woo J.K.S., Lee J.C.K., Huang D.P. Hypermethylation of the p16 gene in nasopharyngeal carcinoma. Cancer Res. 56:1996;2721.
51. Takita J., Hayashi Y., Kohno T., Yamaguchi N., Hanada R., Yamamoto K., Yokota J. Deletion map of chromosome 9 and p16 (CDKN2A) gene alterations in neuroblastoma. Cancer Res. 57:1997;907.
52. Chedid M., Michieli P., Lengel C., Huppi K., Givol D. A single nucleotide substitution at codon 31 (Ser/Arg) defines a polymorphism in a highly conserved region of the p53-inducible gene WAF1/CIP1. Oncogene. 9:1994;3021.
53. Shiohara M., El-Deiry W.S., Wada M., Nakamaki T., Takeuchi S., Yang R., Dan-Lin C., Vogelstein B., Koeffler H.P. Absence of WAF1 mutations in a variety of human malignancies. Blood. 84:1994;3781.
54. Jonveaux P., Berger R. Infrequent mutations in the p53 gene in primary human T-cell acute lymphoblastic leukemia. Leukemia. 5:1991;839.
55. Hsiao M.H., Yu A., Yeargin J., Ku D., Haas M. Nonhereditary p53 mutations in T-cell acute lymphoblastic leukemia are associated with the relapse phase. Blood. 83:1994;2922.
56. Diccianni M.B., Yu J., Hsiao M., Mukherjee S., Shao L.-E., Yu A.L. Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia. Blood. 84:1994;3105.
57. Wada H., Asada M., Nakazawa S., Itoh H., Kobayashi Y., Inoue T., Fukumuro K., Li Chon C., Sugita K., Hanada R., Akuta N., Kobayashi N., Mizutani S. Clonal expansion of p53 mutant cells in leukemia progression in vivo. Leukemia. 8:1994;53.
58. Lowe S., Ruley H., Jacks T., Housman D. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:1993;957.
59. Fisher D. Apoptosis in cancer therapy: crossing the threshold. Cell. 78:1994;539.
60. Wu J., Ye Z., Darras B. Sensitivity of single-strand conformation polymorphism (SSCP) analysis in detecting p53 point mutation in tumors with mixed cell populations. Am J Hum Genet. 52:1993;1273.
61. Sidransky D., Mikkeisen T., Schwechheimer K., Rosenblum M., Cavenee W., Vogelstein B. Clonal expansion of p53 mutant cells is associated with brain tumor progression. Nature. 355:1992;846.
62. Quesnel B., Preudhomme C., Philippe N., Vanrumbeke M., Dervite I., Lai J., Bauters F., Wattel E., Fenaux P. p16 gene homozygous deletions in acute lymphoblastic leukemia. Blood. 85:1995;657.
63. Takeuchi S., Bartram C., Seriu T., Miller C., Tobler A., Janssen J., Reiter A., Ludwing W., Zimmermam M., Schwaller J. p15/MTS2/lNK4B, p16/MTS1/lNK4A, and p18 genes in acute lymphoblastic leukemia of childhood. Blood. 86:1995;755.
64. ink4A gene inactivation in acute lymphocytic leukemia. Blood. 85:1995;3431.
65. Jagasia M., Sher D.A., Le Moine P.J., Kim D.-H., Moldwin R.L., Smith S.D., Diaz M.O. Deletion of lack of expression of CDKN2 (CDK41/MTS1/INK4A) and MTS2 (INK4B) in acute lymphoblastic leukemia cells reflects the phenotype of the uncultured primary leukemia cells. Leukemia. 10:1996;624.
66. Fizzotti M., Giuseppe C., Simona P., Giulina A., Cristina Q., Franco M., Pier G.P., Coco F. Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia association with adverse prognostic features. Blood. 85:1995;2685.
67. Spruck C., Gonzalez-Zulueta M., Shibata A., Simoneau A.R., Lin M.F., Gonzales F., Tsai Y., Jones P. p16 gene in uncultured tumors. Nature. 370:1994;183.
68. Batova A., Dicciani M.B., Yu J.C., Nobori T., Link M.P., Pullen J., Yu A.L. Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia. Cancer Res. 57:1997;832.
69. LeMaistre A., Lee M., Tarpaz M., Kantarjian H., Freireich H., Deisseroth A., Trujillo J., Stass S. RAS oncogene mutations are rare late stage events in chronic myelogenous leukemia. Blood. 73:1989;889.
70. Senn H., Tran-Thang C., Wondar F., Jiricny M.F., Gratwohl G., Singer E., Weber W., Moroni C. Mutation analysis of the N-ras proto-oncogene in active and remission phase of human actute leukemias. Int J Cancer. 41:1989;59.
71. Neri A., Knowles D., Greco A., McCormick F., Dalla-Favera R. Analysis of RAS oncogene mutations in human lymphoid malignancies. Proc Natl Acad Sci USA, 85:1988;9268.
72. Rodenhuis S., Bos J., Slater R., Behrendt H., van't Veer M., Smets L. Absence of oncogene amplification and occasional activation of N-ras in lymphoblastic leukemia of childhood. Blood. 67:1986;1698.